跳转至内容
Merck
CN

主要文件

查看所有文档

5.04314

硼替佐米

≥98% (LC/MS), solid, 20S proteasome inhibitor, Calbiochem®

别名:

硼替佐米, (R)-3-甲基-1-((S)-3-苯基-2-(吡嗪-2-羧酰胺基)丙酰胺基)丁基硼酸，BTZ，LDP-341，LDP341，MG341，MLN-341，MLN341，PS341，蛋白酶体抑制剂XXII，PS-341，MG-341，Pyz-Phe-boroLeu

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C19H25BN4O4
化学文摘社编号:
179324-69-7
分子量:
384.24
MDL number:
MFCD09056737
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (LC/MS)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze, desiccated (hygroscopic), protect from light
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

硼替佐米,

assay

≥98% (LC/MS)

Quality Level

100

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic), protect from light

color

off-white

solubility

DMSO: 100 mg/mL, ethanol: 2 mg/mL (with sonication)

storage temp.

−20°C

SMILES string

B(O)(O)[C@@H](NC(=O)[C@@H](NC(=O)c2nccnc2)Cc1ccccc1)CC(C)C

InChI

1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1

InChI key

GXJABQQUPOEUTA-RDJZCZTQSA-N

General description

硼替佐米是一种细胞渗透性的二肽基硼酸酯化合物，用作蛋白酶体抑制剂。蛋白酶体系统在细胞蛋白周转中发挥重要作用，对于细胞稳态维持至关重要。硼替佐米可逆结合26S蛋白酶体的胰凝乳蛋白酶样亚基抑制其功能，从而抑制多个促凋亡因子的降解。硼替佐米选择性抑制20S蛋白酶体β5 ChTL/胰凝乳蛋白酶样活性、β1 Cl/胱天蛋白酶样活性和β2 TL/胰蛋白酶样活性（各自的kinact/Ki = 38,000、5,700、<100 M-1s-1，人体20S蛋白酶体检测使用10 M Suc-LLVY-AMC/货号539142，10M Z-LLE-AMC/货号539141，或50M Boc-LRR-AMC作为底物；1小时内各自IC50 = 7, 74和4,200 nM），通过催化β亚基的亲核Thr1羟基/Thr10γ与抑制剂亲电子硼部分之间以一种共价、缓慢可逆方式相互作用而进行抑制，对人胰凝乳蛋白酶、组织蛋白酶G、白细胞弹性蛋白酶和凝血酶展现出的效力大大降低（各自Ki = 0.32, 0.63, 2.3和13 M，对比使用620 nM兔肌肉20S）。一种在体外培养和动物体内中广泛使用的抑制剂。尽管是首个被FDA批准用于临床抗癌治疗的蛋白酶体抑制剂，它的治疗功效仍然受到了脱靶作用和剂量限制性毒性的影响。

Application

硼替佐米已用于诱发小鼠的有氧糖酵解/神经病理性疼痛，研究化疗所致痛性周围神经病变。

Biochem/physiol Actions

可逆性：是
细胞可渗透性：具有

Features and Benefits

  • 细胞可渗透，可靶向作用
  • 可逆调节细胞过程

Packaging

用惰性气体包装

Preparation Note

仅使用新鲜的DMSO或乙醇用于重悬。
在重悬后分装并冻存于冰箱（-20°C.）储备溶液在-20°C下可稳定保存至多6个月。

Other Notes

Du, X.L, and Chen, Q. 2013.Acta Haematol.129, 207.
Tamatani, T., et al. 2013.Int. J. Oncol.42, 935.
Beck, P., et al. 2012.J. Biol. Chem.393, 1101.
Fang, H.T., et al. 2012.Proc.Natl.Acad.Sci. USA.109, 2521.
Chen, D., et al. 2011.Curr.Cancer Drug Targets11, 239.
Demo, S.D., et al. 2007.Cancer Res.67, 6383.
Adams, J., et al. 1999.Cancer Res.59, 2615.
Teicher, B.A., et al. 1999.Cancer Res.5, 2638.
Adams, J., et al. 1998.Bioorg.Med. Chem. Lett.8, 333.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

毒性：标准处理（A）

Still not finding the right product?

Explore all of our products under 硼替佐米

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2

target_organs

Gastro-intestinal system,Nervous system,Blood,Liver,Kidney

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

Protease Inhibitor Selection: Avoid Protein Loss in Sample Prep

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Susan D Demo et al.
Cancer research, 67(13), 6383-6391 (2007-07-10)
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. Here we describe the antitumor activity of PR-171, a
Panjamurthy Kuppusamy et al.
Frontiers in pain research (Lausanne, Switzerland), 5, 1424348-1424348 (2024-07-09)
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment that significantly impacts patients' quality of life. This study investigated the effects of targeting metabolic pathways on bortezomib-induced neuropathic pain and tumor growth using a Lewis lung carcinoma
J Adams et al.
Bioorganic & medicinal chemistry letters, 8(4), 333-338 (1999-01-01)
Potent and selective dipeptidyl boronic acid proteasome inhibitors are described. As compared to peptidyl aldehyde compounds, boronic acids in this series display dramatically enhanced potency. Compounds such as 15 are promising new therapeutics for treatment of cancer and inflammatory diseases.
查看所有相关文献

全球贸易项目编号

货号GTIN
463159-1G04061832355115
504314000104055977263923